Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investor Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
Investors and interested parties can access the live webcast of the fireside chat through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the website for 90 days following the event, providing an opportunity for those unable to attend the live session to catch up on the discussion.
Positive
- None.
Negative
- None.
News Market Reaction – ABOS
On the day this news was published, ABOS declined 2.04%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) participating in the H.C. Wainwright Global Investor Conference?
What is Acumen Pharmaceuticals (ABOS) developing?
How can investors access Acumen Pharmaceuticals' (ABOS) fireside chat at the conference?
What stage of development is Acumen Pharmaceuticals (ABOS) currently in?
